Our in vitro and in vivo analysis, the WB results suggested that CD44-shRNA/DDP/MFH might promote cell apoptosis by downregulating the expression of survivin, Bcl-2, and Bcl-xl protein and upregulating the expression of caspase-3 and caspase-9 protein (which were all known as proliferation or apoptosis biomarkers); also, it inhibits tumor neovascularization by inhibiting the expression of VEGF protein, thus inhibiting ovarian cancer tumor growth, invasion, and migration. This evidence concerns the gene CASP9 and neoplasm.